Hepatic stellate cells increase in *Toxoplasma gondii* infection in mice

Hasan Tarık Atmaca¹, Aycan Nuriye Gazıyagcı³, Sila Canpolat¹ and Oguz Kul¹,²

Abstract

**Background:** *Toxoplasma gondii* is a ubiquitous protozoan parasite that can infect humans and animals. The severity of toxoplasmosis varies according to the immune status of the individual, parasite strain, and host species. In mammalian species, it has been observed that severe lesions of acute toxoplasmosis form in visceral organs such as the liver, lung, and spleen. Some epidemiological studies have reported an association of *T. gondii* infection with liver cirrhosis.

**Methods:** Acute infection was induced in fifteen 30-day-old normal Swiss albino mice. The mice were infected by intraperitoneal inoculation of 5000 *T. gondii* RH strain tachyzoites. The mice were sacrificed in groups of 5 at 2, 4, and 6 days after inoculation. Another group of 5 mice were used as the controls. Anti-glial fibrillary acidic protein (GFAP) and anti-*T. gondii* antibodies were used to compare GFAP-immunoreactive cells and anti-*T. gondii*–immunopositive areas in the liver between the *T. gondii*-infected groups and the healthy controls, respectively.

**Results:** There was a significant correlation between the numbers of GFAP-positive hepatic stellate cells (HSCs) when they were compared with *T. gondii* antigen immunostaining (p < 0.05). The amount of *T. gondii* immunostaining increased significantly with the increase in the number of HSCs.

**Conclusions:** There is a significant relationship between the number of HSCs and *T. gondii* antigens, which may represent an active role of HSCs in liver pathology and the pathobiology of *T. gondii*-related hepatitis.

**Keywords:** *Toxoplasma gondii*, Liver, Hepatic stellate cell, Hepatitis, Acute

Background

Toxoplasmosis is a parasitic disease caused by the protozoan *Toxoplasma gondii*. It can infect humans and animals [1,2]. Typically, infection occurs after ingestion of raw or undercooked meat containing tissue cysts or through accidental environmental contamination by oocysts. Only a small percentage of humans and animals display clinical symptoms following infection. The severity of toxoplasmosis varies according to the immune status of the individual, parasite strain, and host species [2-5]. Severe lesions due to acute toxoplasmosis have been observed in visceral organs such as the liver, lung, and spleen of mammalian species [6]. It is known that the parasite locates to the host liver, lymph nodes, eyes, heart, and central nervous system, causing the lesions. In the liver, it causes pathological changes that progress to hepatomegaly, granuloma, hepatitis, and necrosis. Some epidemiological studies have reported an association of *T. gondii* infection with liver cirrhosis [7]. An important functional role of stellate cells in liver repair as indicated by the close proximity of this cell type to collagen fibers in injured livers [8]. Hepatic stellate cells are known to play an important role in the development of fibrosis and its advancement to cirrhosis. Activated hepatic stellate cells differentiate from vitamin-A-storing cells to contractile myofibroblastic cells responsible for extracellular matrix (ECM) production in the damaged liver. There is rising evidence mainly from the experimental studies that HSCs acquire signaling pathways required for stem/progenitor cell functions [9]. Hepatic stellate cells can also interact with the sinusoidal space, where other antigen presenting cells (APC) such as dentritic cells and liver macrophages or kupffer cells are existent. Therefore, HSC might also affect the Ag-presenting function of these APC [10].
The liver consists of parenchymal and non-parenchymal cells. The non-parenchymal cells include endothelial cells, Kupffer cells, liver-associated natural killer cells, hepatic stellate cells (HSCs), and cholangiocytes [11].

HSCs are defined as mesenchymal cells. These cells contain cytoskeletal proteins such as vimentin, α-smooth muscle actin (α-SMA), desmin, and glial fibrillary acidic protein (GFAP) [12,13]. In this study, we used GFAP to identify HSCs.

To our knowledge, the role of HSCs in acute hepatic lesions caused by *T. gondii* infection has not been investigated before. In this study, we demonstrated the role of HSCs in *Toxoplasma* hepatitis using immunohistochemical tests.

**Methods**

**Study design**

Twenty 30-day-old normal Swiss albino mice, weighing approximately 25–30 g, were used to study acute *T. gondii* infections. They were supplied by, The Turkish Public Health Institution. The virulent *T. gondii* RH strain, which is maintained in the Parasitology Laboratory of the Turkish Public Health Institution by continuous passage every 3–4 days in mice, was used to induce acute infection. Fifteen mice were infected by intraperitoneal inoculation of 5000 *T. gondii* RH tachyzoites. In groups of 5, the mice were sacrificed at 2, 4, and 6 days after inoculation (DAI). Another healthy 5 mice sacrificed at the beginning of study, were used as the control in the immunohistochemical tests. The Animal Care Committee of the University of Kırıkale approved this study. (permission date:11.02.2011, no. 11).

**Necropsy and histopathology**

Mice were sacrificed by cervical dislocation after they had been anesthetized with pentobarbital. The livers were removed and fixed in 10% formaldehyde in 0.1 M phosphate buffer. The fixed tissue was dehydrated and embedded in paraffin. The livers were sectioned to 5-µm thickness and stained with hematoxylin and eosin (H&E).

**Immunohistochemistry**

HSCs were stained for immunohistochemistry (IHC) using 1:50 rabbit polyclonal anti-GFAP antibody (Thermo Fisher Scientific Inc., USA). *Toxoplasma* antigens were demonstrated as described previously [14] using 1:100 rabbit anti- *T. gondii* antibody. All immunohistochemical tests were performed according to a commercial streptavidin–biotin kit (Thermo Fisher Scientific Inc.) protocol that used diaminobenzidine (DAB) as a chromogen and Mayer’s haematoxylin as a counterstain. Mouse brain experimentally infected with the *T. gondii* Me49 strain served as a positive internal control for the GFAP and *T. gondii* antigens. The negative control underwent the same process, but in the absence of the primary antibody during the staining procedure. Sections on poly-L-lysine-coated slides were deparaffinized. Endogenous peroxidase blocking was carried out using 3% hydrogen peroxide in methyl alcohol for 10 min. Heat retrieval was carried out using Tris buffer solution (TBS, pH 6.0) in a pressure cooker. The protein blocking stage spanned 7 min. Treatment with the primary antibody (anti-GFAP or anti-*T. gondii*) on the positive control slides was carried out for 1 h, followed by secondary antibody for 30 min, and finally with streptavidin for 30 min. Slides were rinsed with TBS (2 × 5 min) after each step. Sections were treated with DAB for 10 min and counterstained with Mayer’s haematoxylin. Microphotographs were captured using an Olympus BX51 microscope with a DP25 camera attachment (Japan).

**Histomorphometric analysis and statistics**

Leica QWin Plus image processing and analysis software (Leica, Germany) was used to evaluate the intracellular and interstitial immunostaining. Briefly, at least 5 randomly selected and consecutive × 20 objective microscope fields were photographed. After calculation of the proportional (% pixels) staining area to whole fields, the mean % pixels staining area for each slide was calculated. To evaluate non-parametric data, the Mann–Whitney *U*-test was used to compare GFAP-immunoreactive cells and anti-*T. gondii*–immunopositive areas in the liver between the *T. gondii*-infected groups and the healthy controls. The relationship between the HSCs and *T. gondii* antigens were assessed using the Kruskal–Wallis test. A p-value of <0.05 was considered statistically significant.

**Results**

**Histopathology**

The control H&E-stained liver sections exhibited normal hepatic architecture. In *T.gondii*-infected mice, there were multiple foci of hepatocellular necrosis and mononuclear cell infiltrations (Figure 1). Mild lymphocytic and plasma cell infiltrations were found in the periportal areas and around the central veins. A few tachyzoite clusters were present in the cytoplasm of the hepatocytes. Some hepatocytes were filled with a large group of parasites (Figure 2). Karyorrhexis and karyolysis were observed in the nuclei of necrotic hepatocytes (Figure 3).

Several small inflammatory lesions were present on the surface of the liver, increasing in number and progressing into deeper areas over time after inoculation (Figure 3). While it was difficult to identify individual parasites in tissue sections at 2 DAI, the parasites were easily identified after immunohistochemical staining. At 4 and 6 DAI, parasite clusters became apparent in both hepatocytes (H&E) and stellate cells (GFAP, IHC). Small
numbers of parasites were associated with the connective tissue on the surface of the liver during the early stages of infection at 2 DAI. There was a massive increase in the numbers of parasites associated with the connective tissue at 4 and 6 DAI as compared to that at 2 DAI. The parasites were also present along the connective tissue strands within the liver. The initial inflammatory lesions contained few parasites, but these increased rapidly over time, becoming numerous at 4 DAI. In addition, a number of hepatocytes and sinusoidal cells were infected, and a number of these contained large groups of parasites.

**T. gondii IHC**

The statistical evaluation of *T. gondii* antigen expression in the liver of *T. gondii*-infected and control animals is listed in Table 1. *T. gondii* antigens were detected in all infection groups. At 2 DAI, positive immunoreactions were observed at the surface and underside of Glisson’s capsule. At 4 and 6 DAI, necrotic foci, hepatocytes, and HSCs containing tachyzoites were *T. gondii* antigen–immunopositive (Figures 4 and 5). *T. gondii* antigen immunoreactivity was not detected in specific locations. Immunopositive reactions were observed throughout the lobules.

**HSCs detected by GFAP IHC**

The statistical evaluation of GFAP antigen expression in the HSCs of *T. gondii*-infected and control animals are listed in Table 1. The number of HSCs was highest (3.609) in the 6 DAI group as compared to 3.090, 2.515, and 0.902 in the 4 DAI, 2 DAI, and control groups, respectively (p < 0.05). There was a significant correlation between the numbers of GFAP-positive HSCs when they were compared with *T. gondii* antigen immunostaining (p < 0.05). The amount of *T. gondii* immunostaining increased significantly along with the increase in the number of HSCs (Table 1).

The anti-GFAP antibody produced thin, irregular immunopositive bands that lined the hepatic sinusoids of the control animals (Figure 6). GFAP-positive HSCs were present within the perisinusoidal space of Disse in the liver, which is lined by parenchymal cells and fenestrated sinusoidal endothelial cells (SECs). We observed a significantly higher number of GFAP-positive HSCs at 2, 4, and 6 DAI, with activated stellate cells in the periportal, intermediate, and periacinar areas (Figure 7). The GFAP-positive HSCs also contained numerous proliferating parasites (Figure 8).

**Discussion**

To our knowledge, this is the first experimental study of acute *T. gondii* infection analyzing HSC activation and its correlation with *T. gondii*-associated lesions in the
liver. We carried out immunohistochemical analysis of the number of activated HSCs as detected by GFAP staining. The number of activated HSCs was significantly higher in the *T. gondii* infection groups than that in the healthy group.

Acute liver injury was followed by an almost exclusive increase in the number of HSCs, while HSCs as well as liver myofibroblasts were involved in scar formation in chronically injured livers [15].

Intravital microscopy imaging studies have determined that apicomplexan parasites such as *T. gondii* invade the liver, gradually move toward the surface of sinusoidal epithelial cells to the Kupffer cells, finally entering and developing in the cytoplasm of hepatocytes [16].

GFAP expression decreases upon HSC activation, whereas desmin and α-SMA levels increase due to HSC transformation into myofibroblast-like cells [17]. In this study, increased GFAP immunopositive HSCs were related to the *Toxoplasma gondii* infection in the mice. Additionally, the increased GFAP immunopositivity in the lesions and perisinusoidal region suggests the accumulation of HSCs at locations of active initial fibrogenesis.

The nature of stellate cells, traditionally considered cells of mesenchymal origin due to their morphologic features and their expression of molecules such as vimentin, desmin, and α-SMA, has been questioned recently, as numerous studies have clearly demonstrated the expression of neural and neuroendocrine markers such as GFAP, nestin, neurotrophin receptor, and synaptophysin [18].

In the normal liver, HSCs comprise approximately 1.4% of the total liver volume and are present at a ratio of approximately 3.6–6 cells per 100 hepatocytes (1:20). HSCs are typically located in the perisinusoidal space of Disse, a recess between SECs and hepatocytes [18]. We demonstrated activated HSCs using a specific polyclonal antibody to detect GFAP. GFAP is an early marker of stellate cell activation in the liver [19] and has been suggested as a more reliable marker for perisinusoidal stellate cells than desmin [20]. Buniatian *et al.* showed both GFAP and vimentin were strongly expressed in the perinuclear region and the cell processes of cultured stellate cells. They also demonstrated staining for GFAP highly overlapped with that for vimentin or desmin in cultured stellate cells and with that for vimentin in the liver sections. Desmin-positive cells were always also GFAP-positive [20].

However, of the GFAP-positive cells only an estimated 50% were found desmin-positive. In addition, GFAP has been established as one of several markers for identifying HSCs [21].

Ueberham *et al.* were the first to demonstrate the proliferation of midzonal and pericentral HSC populations [22]. They demonstrated the proliferative state of

---

**Table 1 GFAP and *T. gondii* immunohistochemical test results and statistical data**

| Antibody       | Control (n = 5) | 2 DAI (n = 5) | 4 DAI (n = 5) | 6 DAI (n = 5) | Statistical significance p* |
|----------------|----------------|--------------|--------------|--------------|-----------------------------|
|                | Mean           | Std. deviation | Mean         | Std. deviation | Mean           | Std. deviation | Mean           | Std. deviation | p*** |
| GFAP           | 0.902          | 0.080         | 2.515        | 0.383         | 3.090          | 0.171         | 3.609          | 0.316         | <0.05 |
| *T. gondii*    | 0              | 0             | 3.538        | 0.440         | 4.136          | 0.218         | 4.632          | 0.337         | <0.05 |

DAI days after infection, GFAP Glial fibrillary acidic protein, *T. gondii* *Toxoplasma gondii*.

*p* Mann-Whitney test.

**Kruskal-Wallis test.

---

**Figure 4** Anti-*Toxoplasma gondii* antigen immunopositivity throughout the liver, in necrotic foci, and individual hepatocytes. Diaminobenzidine chromogen and hematoxylin counterstain. Bar: 50 micrometer.

**Figure 5** Anti-*Toxoplasma gondii* antigen immunopositivity in individual hepatocytes. Diaminobenzidine chromogen and hematoxylin counterstain. Bar: 20 micrometer.
distinct sinusoidal cell populations by double-labeling experiments, merging bromodeoxyuridine staining with GFAP in the liver sections of choline-deficient, ethionine-treated mice. The increase of HSCs in Toxoplasma hepatitis can be described easily. The number of HSCs detected increased at 2 DAI, and continued to increase at 4 and 6 DAI. These data are analogous to the T. gondii antigen. This means that as the amount of T. gondii antigen increased, the number of HSCs and histopathological lesions in the liver increased in tandem.

An increasingly complex interplay between various cell types in the liver and stellate cells has become apparent. Hepatocytes, Kupffer cells, platelets, epithelial cells, SECs, and neutrophils are known to interact with stellate cells. Each of these cell types will release a subset of mediators that have diverse effects on HSCs [18]. We are curious as to whether HSCs also release mediators. Future studies may help to determine or describe the interaction of cytokine or mediator-releasing HSCs in liver disease, including T. gondii infection. Moreover, double immunohistochemical staining, that can be defined as the detection of two or more targets on one slide, thus increasing the information obtained from each tissue section, can be performed on HSCs.

It is widely accepted that HSCs contribute to liver fibrosis. HSCs reside within the perisinusoidal space of Disse in the liver lined by parenchymal cells and fenestrated SECs. HSCs can develop into myofibroblast-like cells that synthesize extracellular matrix proteins and contribute to liver fibrosis [8,23-25].

Another experimental study has yielded similar information, determining that HSCs are directly involved in the restoration of liver mass even in vivo [26]. Rastogi et al. [9] reported a possible dynamic role of HSCs in liver regeneration and the pathobiology of acute-on-chronic liver failure. Our study also highlights the probability that HSCs play an important role in liver regeneration. This is because the proliferation of parasites in HSCs and the number of HSCs increase in parallel. This may indicate the beginning of liver regeneration with HSCs. We do not know how HSCs can play a role in treated liver injury from this study. After successful treatment of T. gondii infection in liver, we would like to see the regeneration and the status of hepatic stellate cells.

Future studies in liver diseases of different etiologies and stages using immunohistochemical markers and molecular studies of HSCs are needed to confirm these initial observations, and might provide further insight.
into liver injury and repair mechanisms and may help to improve therapeutic interventions in liver diseases associated with *T. gondii*.

**Conclusions**

Thus, the number of activated HSCs in hepatitis due to *T. gondii* was found to be higher than healthy liver. There is a significant relationship between the number of HSCs and *T. gondii* antigens, which may represent an active role of HSCs in liver pathology and the pathobiology of *T. gondii*-related hepatitis. In addition, the findings from this study would be useful for investigations of experimentally induced liver lesions in mice.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

HTA conceived the study and wrote the manuscript. ANG and SC performed the experiments. OK assisted with the statistics. All authors read and approved the final manuscript.

**Acknowledgements**

A professional editor edited the language in this manuscript (Nikesh Gosalia, EC) and a professional editor edited the language in this manuscript (Nikesh Gosalia, EC).

**Author details**

1. Permanent address: Department of Pathology, Faculty of Veterinary Medicine, University of Kırkale, Kırkale 71451, Turkey. 2. Present address: Department of Pathology, Faculty of Veterinary Medicine, Kirkgsztan-Turkey Manas University, Bishkek 720044, Kyrgyzstan. 3. Department of Parasitology, Faculty of Veterinary Medicine, University of Kırkale, Kırkale 71451, Turkey.

**Received:** 12 February 2013 **Accepted:** 30 April 2013 **Published:** 4 May 2013

**References**

1. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of *Toxoplasma gondii* in man and animals. Anim Health Rev 2005, 6:41–61.
2. Dubey JP. *Toxoplasmosis of animals and humans*. 2nd edition. Boca Raton: Florida CRC Press; 2009.
3. Montoya JG, Liesenfeld O. *Toxoplasmosis*. Lancet 2004, 363:1965–1976.
4. Dawson D. *Foodborne protozoan parasites*. Int J Food Microbiol 2005, 103:207–227.
5. Dubey JP, Jones JL. *Toxoplasmosis gondii* infection in humans and animals in the United States. Int J Parasitol 2008, 38:1257–1278.
6. Weiss LM, Kari K. *Toxoplasma gondii*–The model apicomplex: perspectives and methods. Eds. London: Academic Press, Elsevier; 2007.
7. Alvarado-Esquivel C, Torres-Berumen JL, Estrada-Martínez S, Liesenfeld O, Mercado-Suárez MF. *Toxoplasmosis gondii* infection and liver disease: a case-control study in a Northern Mexican Population. Parasit Vectors 2011, 4:75.
8. Friedman SL. Hepatic stellate cells: protein, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125–172.
9. Rastogi A, Bihari C, Mawill R, Ahuja A, Sharma MK, Kumar A, Sarin SK. Hepatic stellate cells are involved in the pathogenesis of acute-on-chronic liver failure (ACLF). Vlchows Arch 2012, 461:393–398.
10. Ichikawa S, Mucida D, Tymik AJ, Kronenberg M, Cheroutre H. Hepatic stellate cell function as regulatory bystanders. J Immunol 2011, 186:50549–5055.
11. Bouwens L. Proliferation and phenotypic expression of non-parenchymal liver cells. Scand J Gastroenterol 1988, 2346–51.
12. Sappino AP, Schurc W, Gabbiani G. Biology of disease. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal protein as marker of phenotypic modulations. Lab Invest 1990, 63:144–161.
13. Tsutsui M, Takada A, Takase S. Characterization of desmin-positive rat liver sinusoidal cells. Hepatology 1987, 7:277–284.
14. Hazirouglu R, Altintas K, Atasever A, Gulbahar MY, Kile O, Tunca R. Pathological and immunohistochemical studies in rabbits experimentally infected with *Toxoplasma gondii*. Turk J Vet Anim Sci 2003, 27:285–293.
15. Kottel T, Kobold D, Picaglia F, Saile B, Neubauer K, Meide M, Timpl R, Ramadori G. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochern Cell Biol 1999, 112:387–401.
16. Frevert U, Engelmann S, Zougbdeld S, Stange J, Ng B, Matuschewski K, Liebes L, Yee H. Intravital observation of *Plasmodium berghei* sporozoite infection of the liver. PLoS Biol 2005, 3:e192. doi:10.1371/journal.pbio.0030192.
17. Campbell JS, Hughes DG, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Oddel MM, Bauer RL, Ren HP, Haugen HS, Yeh MW, Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2005, 102:3389–3394.
18. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007, 131:1728–1734.
19. Morini S, Carotti S, Carpino G, Franchitto A, Corradini SG, Merli M, Gaudio E. GFAP expression in the liver as an early marker of stellate cell activation. J Immunol 2009, 182:7582–7591.
20. Buniatian G, Gebhardt R, Schenk D, Hamprecht B. Colocalization of three types of intermediate filament proteins in perisinusoidal stellate cells: glial fibrially acidic protein as a new cellular marker. Eur J Cell Biol 1996, 70:23–32.
21. Maubach G, Lim MC, Zhang CY, Zhuo L. GFAP promoter directs lacZ expression specifically in a rat hepatic stellate cell line. World J Gastroenterol 2006, 12:723–730.
22. Uiberham E, Bötger J, Uiberham U, Grosche J, Gebhardt R. Response of sinusoidal mouse liver cells to choline-deficient ethionine-supplemented diet. Comp Hepatol 2010, 9:8.
23. Burt AD. *Pathobiology of hepatic stellate cells*. J Gastroenterol 1999, 34:299–304.
24. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000, 32:31 Suppl:[32–38.
25. Geerts PD. History, heterogeneity, developmental, biology, and functions of quiescent hepatic stellate cells. Sem Liver Dis 2001, 21:313–335.
26. Yang L, Jung Y, Omenetti A, Witek RP, Choi S, Vandongen HM, Huang J, Alpini GD, Denti AM. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells 2008, 26:2104–2113.

doi:10.1186/1756-3305-6-135

**Cite this article as:** Atmaca et al.: Hepatic stellate cells increase in *Toxoplasma gondii* infection in mice. Parasites & Vectors 2013 6:135.